Special Issue "Women's Special Issue Series: Recent Development for Improved Therapeutic Antibodies"
A special issue of Antibodies (ISSN 2073-4468).
Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 18151
Therapeutic monoclonal antibodies were first approved for cancer therapy about 25 years ago. Since then, may antibody-based molecules have been developed and tested in the clinic, and at least 110 molecules have been approved in the US/EU for the therapy of cancer as well as inflammatory, autoimmune, and infectious diseases. To reach this goal, much basic work has been performed in laboratories worldwide, to try to understand how antibody-based drugs work, how to improve their activities, their stability, diminish their toxicity, and facilitate their production. In parallel, many studies have focused on the structure and fine-tuning of natural antibodies, and some of this knowledge has already been applied to improve antibody-based drugs. The aim of this issue is to review recent discoveries that have or are likely to have a significant impact on the successful development of novel or improved therapeutic antibodies in different disease contexts.
We have chosen women scientists for this task. However, we welcome submissions from all authors, irrespective of gender identity.
Dr. Josee Golay
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- therapeutic antibodies
- natural antibodies
- antibody variants
- antibody structure